Table of Contents
Table of Contents
Preface
1. Targeting HER2 with Photodynamic Therapy, PP.1-46
(Ján Kovaľ, Peter Solár, Jaromír Mikeš, Rastislav Jendželovský, Peter Fedoročko, Faculty of Sciences, Institute of Biology and Ecology, P. J. Šafárik University in Košice, Košice, Slovakia)
2. Investigating Molecular Mechanisms of Specificity in Regulation of the HER2 Receptor Tyrosine Kinase through Molecular Modeling and Simulation, pp.47-80
(Shannon E. Telesco, Andrew Shih, Yingting Liu, Ravi Radhakrishnan, Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania, USA)
Free Download Available
3. The HER2 Shedding and its Consequences on Breast Cancer, pp.81-100
(Pierre-Jean Lamy, Anne-Sophie Gauchez, Chantal Tse, Department of Clinical Biology and Oncogenetic, Val d’Aurelle-Paul Lamarque Cancer Center , Montpellier, France, and others)
4. The Role of HER2 in Targeted Cancer Therapy and Hypothesized Future Perspectives. pp. 101-122
(Luca Monfregola, Stefania De Luca, Istituto di Biostructure e Bioimmagini IBB-CNR, Naples, Italy)
5. HER2 Positive Primary Breast Cancer in Older Women: Clinical Significance and Therapeutic Challenge, pp. 123-144
(B.M. Syed, R. Leonard, I.O. Ellis, K.L. Cheung, Divisions of Breast Surgery and Pathology, University of Nottingham, and Imperial College London, United Kingdom)
6. Influence of Psychological Stress on Initiation, Progression, Metastasis in Breast Cancer, pp.145-160
(Ming Shi, Lu Qian, Beifen Shen, Ning Guo, Department of Molecular Immunology, Institute of Basic Medical Sciences, Beijing, P.R. China)
7. Development of Trastuzumab Resistance: Is it Only in Signaling?
(Timothy Kute, John Stehle, Department of Pathology, Wake Forest University Baptist Medical Center, Winston Salem, North Carolina, and others)pp.161-174
Free Download Available
8. Targeted Nanomedicines Conjugated with HER2 Antibodies in Cancer Therapy, pp.175-186
(Jie Gao, Bohua Li, Wei Li, Jianxin Dai, Hao Wang, Yajun Guo, Cancer Institute of the Second Military Medical University, Shanghai, People’s Republic of China, and others)
9. Topoisomerase II-Alpha Index Predicts the Efficacy of Anthracycline-Based Chemotherapy for Breast Cancers, pp.187-200
(Kiyomi Taniyama, Nao Morii, Kazuya Kuraoka, Akihisa Saito, Toshinao Nishimura, Junichi Sakane, Mieko Harada, Miho Tanaka, Hiroyo Takahashi, Kazuaki Miyamoto, Hironori Kato, Institute for Clinical Research, Departments of Diagnostic Pathology, Breast Surgery and Surgery, National Hospital Organization, Kure Medical Center and Chugoku Cancer Center, Kure, Japan)
Free Download Available
10. Role of Δ16HER2 Splice Variant in Breast Tumor Progression and Response to HER2-Targeted Therapy, pp.201-210
(Serenella M. Pupa, Manuela Campiglio, Anna Rossini, Rosaria Orlandi, Valentina Ciravolo, Augusto Amici, Elda Tagliabue, Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy, and others)
Free Download Available
11. Molecular Profiling of HER2-Related Protein Networks in Formalin-Fixed and Paraffin-Embedded Cancer Tissues, pp.211-216
(Daniela Berg, Karl-Friedrich Becker, Technische Universität München, Institut für Pathologie, Trogerstrasse, München, Germany)
12. HER2 & the ErbB Network pp.217-230
(Joel Kochanski, Mylin Torres and Ryan Ballenger)
Index
